PMID-35457148 – MGF Accelerates ACL Repair via Rac1-RhoA
Sha Y, Yang L, Lv Y. MGF E peptide improves anterior cruciate ligament repair by inhibiting hypoxia-induced cell apoptosis and accelerating cell migration via the Rac1-PAK1/2 and RhoA-ROCK1 signaling pathways. J Cell Physiol. 2022;237(8):3269-3282.
Quick Reference
| Property | Value |
|---|---|
| PMID | 35457148 |
| DOI | 10.1002/jcp.30782 |
| Year | 2022 |
| Journal | International Journal of Molecular Sciences |
| Study Type | In vitro |
| Evidence Level | V (Oxford CEBM) |
| Sample | Human ACL fibroblasts |
| Peptide(s) Studied | PEG-MGF |
Key Findings
- MGF E peptide significantly improved cell migration in injured human anterior cruciate ligament (ACL) fibroblasts, a key process for ligament healing
- Enhanced cell adhesion was observed, supporting the structural repair process in damaged ligament tissue
- The mechanism involves activation of the Rac1-PAK1/2 signaling pathway, promoting cytoskeletal reorganization and directed cell movement
- Concurrent activation of the RhoA-ROCK1 pathway contributed to cell contractility and adhesion, complementary to the Rac1 migratory signal
- MGF inhibited hypoxia-induced apoptosis in ACL fibroblasts, protecting cells in the ischemic injury microenvironment
- This study extends MGF's established role from skeletal muscle repair to connective tissue (ligament) repair, broadening its therapeutic applications
Study Design
In vitro study using primary human ACL fibroblasts obtained from patients undergoing ACL reconstruction surgery. Cells were cultured under normoxic and hypoxic conditions to simulate the injury microenvironment. MGF E peptide was applied at varying concentrations. Cell migration was assessed using wound healing (scratch) assays and transwell migration assays. Cell adhesion was quantified using fibronectin-coated plate adhesion assays. Apoptosis was measured by flow cytometry and caspase activity assays. Signaling pathway involvement was confirmed using specific inhibitors of Rac1, PAK1/2, RhoA, and ROCK1.
Limitations
- In vitro study using isolated fibroblasts, which does not recapitulate the complex in vivo ligament healing environment
- Primary cells from patients undergoing ACL reconstruction may not represent all ACL injury populations
- The MGF E peptide concentration used in vitro may not be achievable in the ligament microenvironment with systemic administration
- No comparison between native MGF peptide and PEG-MGF formulation
- Single time-point assessments may not capture the dynamic process of ligament healing
- No in vivo validation of the ACL repair enhancement
Clinical Relevance
This study provides mechanistic evidence for MGF's utility in connective tissue repair beyond muscle, specifically in ACL injury — one of the most common sports injuries. The dual-pathway mechanism (Rac1-PAK1/2 for migration + RhoA-ROCK1 for adhesion) offers a detailed scientific rationale for including PEG-MGF in ligament and tendon repair protocols. Combined with BPC-157 and TB-500 (which promote angiogenesis and inflammation modulation respectively), PEG-MGF could address the cell migration and adhesion components of connective tissue repair. Directly supports the Wolverine Stack Protocol rationale and Module 3 (Tissue Repair) curriculum.
Related
#research #in-vitro #evidence-level-V #peg-mgf #recovery #musculoskeletal